Hugo Ford

2.1k total citations · 1 hit paper
32 papers, 1.1k citations indexed

About

Hugo Ford is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Hugo Ford has authored 32 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 14 papers in Surgery. Recurrent topics in Hugo Ford's work include Colorectal Cancer Treatments and Studies (15 papers), Gastric Cancer Management and Outcomes (15 papers) and Esophageal Cancer Research and Treatment (8 papers). Hugo Ford is often cited by papers focused on Colorectal Cancer Treatments and Studies (15 papers), Gastric Cancer Management and Outcomes (15 papers) and Esophageal Cancer Research and Treatment (8 papers). Hugo Ford collaborates with scholars based in United Kingdom, United States and Germany. Hugo Ford's co-authors include David Cunningham, Ian Chau, Janet Dunn, Andrea Marshall, Natalie Cook, Gary Middleton, Tobias Janowitz, Stephen Falk, Jane Blazeby and John Bridgewater and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and The Lancet Oncology.

In The Last Decade

Hugo Ford

29 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

2013 405 citations Hugo Ford, Andrea Marshall et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hugo Ford United Kingdom	16	775	723	328	157	142	32	1.1k
Wilson Luiz da Costa Brazil	14	364 0.5×	403 0.6×	291 0.9×	91 0.6×	125 0.9×	68	785
Antonia Strippoli Italy	17	438 0.6×	532 0.7×	328 1.0×	96 0.6×	134 0.9×	66	1.1k
Young‐Tae Ju South Korea	19	415 0.5×	398 0.6×	522 1.6×	152 1.0×	209 1.5×	80	1.2k
Kuhn‐Uk Lee South Korea	8	410 0.5×	417 0.6×	256 0.8×	138 0.9×	56 0.4×	9	714
Yoh Isobe Japan	16	1.2k 1.5×	434 0.6×	827 2.5×	482 3.1×	181 1.3×	38	1.7k
Giovanni Sgroi Italy	13	654 0.8×	1.1k 1.5×	784 2.4×	129 0.8×	80 0.6×	31	1.5k
Neal Wilkinson United States	18	490 0.6×	410 0.6×	677 2.1×	107 0.7×	73 0.5×	40	1.0k
Xuechao Liu China	17	416 0.5×	437 0.6×	275 0.8×	124 0.8×	66 0.5×	31	770
Jean–Louis Jouve France	15	307 0.4×	374 0.5×	403 1.2×	144 0.9×	55 0.4×	31	884
M.-H. Ryu South Korea	13	364 0.5×	295 0.4×	196 0.6×	140 0.9×	85 0.6×	27	578

Countries citing papers authored by Hugo Ford

Since Specialization

Citations

This map shows the geographic impact of Hugo Ford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugo Ford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugo Ford more than expected).

Fields of papers citing papers by Hugo Ford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hugo Ford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugo Ford. The network helps show where Hugo Ford may publish in the future.

Co-authorship network of co-authors of Hugo Ford

This figure shows the co-authorship network connecting the top 25 collaborators of Hugo Ford. A scholar is included among the top collaborators of Hugo Ford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hugo Ford. Hugo Ford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Janjigian, Yelena Y., Hanneke W. M. van Laarhoven, Sun Young Rha, et al.. (2025). Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA).. Journal of Clinical Oncology. 43(4_suppl). 448–448. 1 indexed citations

Janjigian, Y. Y., Hanneke W.M. van Laarhoven, Sun Young Rha, et al.. (2024). 1401O Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03). Annals of Oncology. 35. S878–S878. 11 indexed citations

Janowitz, Tobias, Peter Thuss-Patience, Andrea Marshall, et al.. (2016). Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. British Journal of Cancer. 114(4). 381–387. 41 indexed citations

Silva, Nadeera de, Anna Paterson, Maria Secrier, et al.. (2015). Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma. British Journal of Cancer. 113(9). 1305–1312. 17 indexed citations

Meads, David, Andrea Marshall, Claire Hulme, Janet Dunn, & Hugo Ford. (2015). The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial. PharmacoEconomics. 34(1). 33–42. 5 indexed citations

Hickish, Tamas, Jim Cassidy, David Propper, et al.. (2014). A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer. 50(18). 3136–3144. 19 indexed citations

Abbadi, Reyad, Umar Sadat, Asif Jah, et al.. (2014). Improved long‐term survival after resection of colorectal liver metastases following staging with FDG positron emission tomography. Journal of Surgical Oncology. 110(3). 313–319. 10 indexed citations

Ford, Hugo, Andrea Marshall, Jonathan Wadsley, et al.. (2013). COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.. Journal of Clinical Oncology. 31(4_suppl). LBA4–LBA4. 20 indexed citations

Ford, Hugo, Andrea Marshall, John Bridgewater, et al.. (2013). Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. The Lancet Oncology. 15(1). 78–86. 405 indexed citations breakdown →

10.

Rassl, Doris M., et al.. (2012). Primitive Neuroectodermal Tumor of the Heart. The Annals of Thoracic Surgery. 93(2). e27–e29. 3 indexed citations

11.

Rollins, Katie E., Christopher J. Peters, Peter Safranek, et al.. (2011). Venous thromboembolism in oesophago-gastric carcinoma: Incidence of symptomatic and asymptomatic events following chemotherapy and surgery. European Journal of Surgical Oncology. 37(12). 1072–1077. 35 indexed citations

12.

Bird‐Lieberman, Elizabeth, Hugo Ford, & Rebecca C. Fitzgerald. (2011). Barrett’s oesophagus and oesophageal adenocarcinoma. Medicine. 39(3). 142–148. 1 indexed citations

13.

Crinò, Lucio, Petr Zatloukal, Martin Reck, et al.. (2007). B3-04: Gefitinib (IRESSA) versus vinorelbine in chemonaïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study. Journal of Thoracic Oncology. 2(8). S341–S341. 19 indexed citations

14.

Ford, Hugo, Yoon Sim Yap, David W. Miles, et al.. (2006). A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 58(6). 809–815. 12 indexed citations

15.

Andreopoulou, Eleni, Paul J. Ross, Mary O’Brien, et al.. (2004). The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Annals of Oncology. 15(9). 1406–1412. 33 indexed citations

16.

Price, Timothy, Paul J. Ross, Tamas Hickish, et al.. (2004). Phase III Study of Mitomycin-C with Protracted Venous Infusion or Circadian-Timed Infusion of 5-Fluorouracil in Advanced Colorectal Carcinoma. Clinical Colorectal Cancer. 3(4). 235–242. 29 indexed citations

17.

Chau, Ian, Mark Allen, David Cunningham, et al.. (2003). 51 The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer: analysis from a prospective randomised controlled trial. European Journal of Cancer Supplements. 1(5). S20–S20.

18.

Ford, Hugo, David Cunningham, David Farrugia, et al.. (2002). Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.. PubMed. 8(1). 103–9. 32 indexed citations

19.

Ford, Hugo, David Cunningham, Paul J. Ross, et al.. (2000). Phase I study of irinotecan and raltitrexed in patients with advanced astrointestinal tract adenocarcinoma. British Journal of Cancer. 83(2). 146–152. 21 indexed citations

20.

Jackman, Ann L., Rosemary Kimbell, & Hugo Ford. (1999). Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations. European Journal of Cancer. 35. S3–S8. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact